SAN DIEGO, June 23, 2015 /PRNewswire/ -- Organovo Holdings,
Inc. (NYSE MKT: ONVO; "Organovo"), a three-dimensional biology
company focused on delivering scientific and medical breakthroughs
using 3D bioprinting technology, announced today that the company
will present at the upcoming investor event, the Cantor Fitzgerald
Inaugural Healthcare Conference, to be held in New York, July
8, 2015. Keith Murphy,
Chairman and Chief Executive Officer, will deliver a company
presentation. Mr. Murphy and Barry
Michaels, Chief Financial Officer for Organovo, will be
available for individual meetings with investors throughout the
day.
Details of the presentations are as follows:
Speakers:
|
Keith Murphy,
Chairman and Chief Executive Officer
|
Date/Time:
|
Wednesday, July 8,
2015, 10:15 – 10:45 a.m. ET
|
Organovo's 3D bioprinting enables the reproducible, automated
creation of living human tissues that mimic the form and function
of native tissues in the body. The company recently announced
collaborations with L'Oreal to produce skin tissue for research and
toxicity testing; with Merck to print liver and kidney tissues for
studies of drug toxicity and with Yale School
of Medicine to develop 3D organ tissues for surgical
transplantation research. Organovo was named one of The World's
Top 10 Most Innovative Companies of 2015 in Health Care by
Fast Company.
An overview of Organovo's 3D bioprinting technology is available
via video presentation at the Company's website:
http://www.organovo.com/investors/investor-overview.
Cantor Fitzgerald's Inaugural Healthcare Conference is a
one-day, multi-track conference featuring presentations from 50+
top tier healthcare companies across the broad continuum of
healthcare. From "bench to bedside", the conference aims to
connect leading public and private healthcare companies with
institutional investors, addressing investment opportunities and
trends shaping healthcare from the earliest stage of development
("bench") to patient treatment ("bedside"). With over 50 publicly
traded companies and numerous private companies available
throughout the day, investors will have the opportunity to expand
knowledge and sharpen investment focus, and participate in 1x1
meetings with company management.
For more information about Organovo's participation in industry
events, please visit:
http://www.organovo.com/tissues-services/upcoming-events.
About Organovo Holdings, Inc.
Organovo designs
and creates functional, three-dimensional human tissues for use in
medical research and therapeutic applications. The Company develops
3D human disease models through internal development and in
collaboration with pharmaceutical and academic partners. Organovo's
3D human tissues have the potential to accelerate the drug
discovery process, enabling treatments to be developed faster and
at lower cost. The company recently launched its initial product of
the planned exVive3D™ portfolio offering, a 3D Human
Liver Tissue for use in Toxicology and other preclinical drug
testing. Additional products are in development, with anticipated
release for an exVive3D™ Human Kidney Tissue in the
latter half of calendar year 2016. The Company also actively
conducts early research on specific tissues for therapeutic use in
direct surgical applications. In addition to numerous scientific
publications, the Company's technology has been featured in The
Wall Street Journal, Time Magazine, The Economist, and numerous
other media outlets. Organovo is changing the shape of medical
research and practice. Learn more at www.organovo.com.
Sign up for email updates and connect with us
on Twitter (@Organovo).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/organovo-holdings-inc-to-present-at-cantor-fitzgerald-inaugural-healthcare-conference-300103435.html
SOURCE Organovo Holdings, Inc.